CD86 and neoplasm: Lida et al. found that germ-free and antibiotic-treated melanoma-bearing mice had impaired anti-tumor immune response after CpG and anti-IL10 receptor (aIL-10R) treatment, as evidenced by reduced TNF production, co-stimulatory CD86 expression, and IL-12 production in tumor-infiltrating immune cells [68].